ALLARITY THERAPEUTICS INC
ALLRNASDAQ🏆 #3595 by market capUS Equity
$1.41▲ $0.00 (+0.00%)
Market closed · at close1h—
24h▲ 0.0%
7d▲ 4.8%
14d▲ 22.6%
30d▲ 23.7%
1y▲ 47.2%
🏦Market Cap
$22M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
53
Weak
Trading Snapshot
- Day Range
- $1.41 – $1.42
- 52-Week Range
- $0.77 – $2.35
- Volume
- $3.46B
- Avg Volume
- $4.11B
- Shares Outstanding
- 15.9M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $534,282
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.72
- Dividend Yield
- —
Why Investors Own ALLR
- ✓High-growth profile — revenue up +17.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2M▲ +21.0% YoY
Gross Margin (TTM)
79.2%▲ +3.9% YoY
Operating Income (TTM)
$384,567▲ +21.0% YoY
Free Cash Flow (TTM)
$547,093▲ +21.0% YoY
About ALLARITY THERAPEUTICS INC
A company profile for ALLARITY THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
53/100
Analyst Price Target
ⓘAverage Target
$1.74
▲ +23.6% Upside
High Target$2.07
Low Target$1.63
Based on 29 analysts
Latest News & Updates
🚀
Barron’s·2h ago
ALLARITY THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift ALLR price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
ALLARITY THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.